Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for TransMedics (TMDX) over the last 2 years, with Q3 2025 value amounting to $15157.0.

  • TransMedics' Gains from Sales and Divestitures rose 101.97% to $15157.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15157.0, marking a year-over-year increase of 101.97%. This contributed to the annual value of -$103372.0 for FY2024, which is N/A changed from last year.
  • TransMedics' Gains from Sales and Divestitures amounted to $15157.0 in Q3 2025, which was up 101.97% from $18893.0 recorded in Q2 2025.
  • In the past 5 years, TransMedics' Gains from Sales and Divestitures registered a high of $111419.0 during Q1 2025, and its lowest value of -$103372.0 during Q4 2024.